Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PROTRANSIT NANOTHERAPY LLC
- Proposal award date
- 2021-06-01
- Contract end date
- 2022-05-31
- UEI
- F32QSKPPN192
- Solicitation number
- PA20-260
- Topic code
- NIAMS
Research abstract
ABSTRACT
This project aims to develop a skincare product to prevent ultraviolet (UV)-induced skin cancer with a novel
antioxidant delivery system, Pro-NP™, for topical application alone or as an additive to commercial sunblock.
Skin cancer is more common than all other cancers combined and affects millions of Americans every year. UV
exposure from the sun or tanning beds causes the production of reactive oxygen species (ROS), which
overwhelms the skin’s natural antioxidant defense and leads to oxidative stress, photoaging, and skin cancer.
While commercial sunscreens can reduce the risk of developing skin cancer, they are poor at blocking UV-A
rays responsible for most of the cutaneous ROS production. The topical application of exogenous antioxidants
could potentially combat UV generated ROS; however, in their native state, many antioxidants are too unstable
to absorb to the deeper layers of the skin effectively. The natural defense system of the skin against UV-induced
oxidative stress includes antioxidants superoxide dismutase (SOD) and catalase (CAT), essential enzymes that
neutralize the detrimental effects of ROS. Unfortunately, the catalytic activity of native SOD and CAT are short-
lived and rapidly cleared, a limiting factor on current therapeutic strategies based on exogenous delivery.
ProTransit has developed a proprietary antioxidant delivery system, Pro-NP™, specially formulated for the slow-
sustained release of SOD and CAT, to overcome the limitation of the antioxidant’s short half-life. The
development of our dermatological product capitalizes on the recent advances of nanotechnology to overcome
the biological barriers of using antioxidants to counteract skin damage caused by ROS. Our preliminary studies
are promising and demonstrate that Pro-NP is non-toxic in humans and penetrates to the deepest layers of
the skin to release active SOD and CAT, reduces DNA damage after UV exposure, and prevents the degradation
of essential skin protein fibers like elastin and collagen. The overall objective of this study is to optimize the
formulation of plant-based SOD and CAT in Pro-NP, determine the window of efficacy, compare the
effectiveness of Pro-NP to commercially available sunscreens, and evaluate the potential of co-application of
Pro-NP with commercial sunscreens. Our long-term goal is to develop novel, next-generation skincare
products for topical application to prevent UV-induced skin damage and ultimately to reduce the incidence of
skin cancer.NARRATIVE
ProTransit is developing a novel, next generation skin care product, Pro-NP™, for the topical application of
nanoformulated super antioxidants to prevent UV-induced skin cancer. Our nanoformulation can penetrate deep
into the skin to counteract oxidative stress that leads to skin damage. Our overall objective is to optimize the
formulation and evaluate the potential to use Pro-NP™ as an additive to commercial sunscreens.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
2 SBIR/STTR records share this UEI (2020–2021). Reported award amounts total $521,088. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards